PROLONGATION OF SURVIVAL IN METASTATIC MELANOMA AFTER ACTIVE SPECIFIC IMMUNOTHERAPY WITH A NEW POLYVALENT MELANOMA VACCINE (VOL 216, PG 463, 1992)

被引：0
|
作者：
MORTON, DL
FOSHAG, LJ
HOON, DSB
机构：
来源：
ANNALS OF SURGERY | 1993年 / 217卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：309 / 309
页数：1
相关论文
共 50 条
  • [1] PROLONGATION OF SURVIVAL IN METASTATIC MELANOMA AFTER ACTIVE SPECIFIC IMMUNOTHERAPY WITH A NEW POLYVALENT MELANOMA VACCINE
    MORTON, DL
    FOSHAG, LJ
    HOON, DSB
    NIZZE, JA
    WANEK, LA
    CHANG, C
    DAVTYAN, DG
    GUPTA, RK
    ELASHOFF, R
    IRIE, RF
    ANNALS OF SURGERY, 1992, 216 (04) : 463 - 482
  • [2] POLYVALENT MELANOMA VACCINE IMPROVES SURVIVAL OF PATIENTS WITH METASTATIC MELANOMA
    MORTON, DL
    HOON, DSB
    NIZZE, JA
    FOSHAG, LJ
    FAMATIGA, E
    WANEK, LA
    CHANG, C
    IRIE, RF
    GUPTA, RK
    ELASHOFF, R
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 690 : 120 - 134
  • [3] Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
    Hsueh, EC
    Nathanson, L
    Foshag, LJ
    Essner, R
    Nizze, JA
    Stern, SL
    Morton, DL
    CANCER, 1999, 85 (10) : 2160 - 2169
  • [4] Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma
    Hsueh, EC
    Essner, R
    Foshag, LJ
    Ye, W
    Morton, DL
    ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (05) : 486 - 492
  • [5] Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma
    Eddy C. Hsueh
    Richard Essner
    Leland J. Foshag
    Wei Ye
    Donald L. Morton
    Annals of Surgical Oncology, 2002, 9 (5) : 486 - 492
  • [6] Active specific immunotherapy with a polyvalent cancer vaccine prolongs survival in AJCC stage IV melanoma.
    Morton, DL
    Essner, R
    Hsueh, EC
    Wanek, LA
    Foshag, LJ
    O'Day, SJ
    Gupta, RK
    Hoon, DS
    Gammon, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 173S - 173S
  • [7] ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA WITH AN ALLOGENEIC MELANOMA VACCINE
    MITCHELL, MS
    KEMPF, RA
    HAREL, W
    SHAU, H
    HADLEY, C
    STAHLBERG, J
    LIND, S
    MOORE, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 409 - 409
  • [8] PHASE-I TRIAL OF SPECIFIC IMMUNOTHERAPY OF MELANOMA WITH A POLYVALENT MELANOMA ANTIGEN VACCINE
    BYSTRYN, JC
    LEVIN, M
    SPEYER, S
    HARRIS, M
    ROSES, D
    BERNSTEIN, P
    CLINICAL RESEARCH, 1984, 32 (02): : A574 - A574
  • [9] PHASE-I TRIAL OF SPECIFIC IMMUNOTHERAPY OF MELANOMA WITH A POLYVALENT MELANOMA ANTIGEN VACCINE
    BYSTTRYN, JC
    LEVIN, M
    SPEYER, S
    HARRIS, M
    ROSES, D
    BERNSTEIN, P
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1984, 82 (04) : 425 - 426
  • [10] Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes
    Morton, DL
    Hsueh, EC
    Essner, R
    Foshag, LJ
    O'Day, SJ
    Bilchik, A
    Gupta, RK
    Hoon, DSB
    Ravindranath, M
    Nizze, JA
    Gammon, G
    Wanek, LA
    Wang, HJ
    Elashoff, RM
    ANNALS OF SURGERY, 2002, 236 (04) : 438 - 449
12345